Hello guys, Welcome to Africa's Largest Video Search Engine, and you are watching The complications of treating elderly patients with AML. and this video is uploaded by VJHemOnc – Video Journal of Hematology & HemOnc at 2018-05-25T07:57:38-07:00. We are just promoting this video only for entertainment and educational purpose only. I hop you like our Video Search Engine. [evTyGwGbXUU]
| Name | The complications of treating elderly patients with AML |
| Video Uploader | Video From VJHemOnc – Video Journal of Hematology & HemOnc |
| Upload Date | This Video Uploaded At 25-05-2018 14:57:38 |
| Video Discription | The average age of people suffering from acute myeloid leukemia (AML) is around 60 to 70 years, and there are many issues surrounding the use of chemotherapy drugs in this population. In this interview, Gail Roboz, MD, from Weill Medical College of Cornell University, New York City, NY, highlights the challenges of AML treatment in the elderly, and some of the options that can be offered to patients in which high dose chemotherapy will not prove beneficial, or patients who have a low tolerance to intensive chemotherapy. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary. [evTyGwGbXUU] |
| Category | Education |
| Tags | Speaker: Gail Roboz | Event: ESH AL 2018 | Format: Interview | Subject: Acute Myeloid Leukemia | Subject: Leukemia | Medicines: Cytarabine | Medicines: Azacitidine | Medicines: Decitabine | Medicines: Venetoclax | Field: Treatment | AML | complications | comorbidities | social issues | challenges | standard regimen | chemotherapy | Ara-C | remission | novel | IDH inhibitor | FLT3 inhibitor | clinical trials | checkpoint inhibitors | hypomethylating agents | preliminary data | combination therapy | elderly |
